NCT05327595View on ClinicalTrials.gov

A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

April 22, 2024

Study Completion Date

April 22, 2024

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3549492

Administered orally.

DRUG

Placebo

Administered orally.

DRUG

Atorvastatin

Administered orally.

DRUG

Midazolam

Administered orally.

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung, Neuss

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY